A closer look at our comprehensive solid-state characterisation and optimisation services:
Our capabilities support every stage of development – from early pre-formulation to commercialisation and lifecycle management. These include:
- Advanced solid-state characterization
- Polymorph screening and tendency studies
- Form setting crystallization development
- Salt selection and optimisation studies
- Co-crystallization and form setting crystallization development
- Impurity control crystallization
- Solubility determination and modelling
- Pre-formulation development
- Solution and solid-state nuclear magnetic resonance (NMR) spectroscopy
- Thermal analysis (DSC, TGA)
- Hygroscopicity (DVS)
- Hot-stage microscopy
- PSD, particle enumeration, surface area
- FT-IR, In-house XRPD, optical microscopy
Advanced equipment that enables rapid, high-quality analysis and decision-making:
We are equipped for flexibility, precision, and scale-up with equipment including:
- X-ray Diffractometer (XRPD)
- Differential Scanning Calorimetry (DSC)
- Thermogravimetric Analysis (TGA)
- Solid-State NMR
- Dynamic Vapour Sorption (DVS)
- FTIR spectroscopy
- Optical microscopy
- Particle size distribution (PSD)
- Surface area analysis
Arcinova: Your partner in solid-state science
Strengthen your formulation with smart salt selection
Enhance bioavailability with tailored amorphous dispersion strategies
When bioavailability is limited by crystallinity, amorphous dispersions offer a proven route to increase dissolution rate and absorption. While crystalline forms provide greater stability, they can underperform when solubility and permeability are critical.
We stabilise amorphous forms using carefully selected excipients and technologies such as spray dried dispersion (SDD) and hot melt extrusion (HME), with development supported by in-house analytics and scalable equipment. We also tailor release profiles – including controlled-release formulations – to suit your therapeutic goals.
Accelerate API isolation and purification through integrated solid-state support
Choosing the right salt or polymorphic form early helps improve yield, purity and process efficiency. Our solid-state team works hand-in-hand with Process Research & Development to rapidly determine salt forms and map polymorphic landscapes to integrate crystallization development with process optimization – ensuring the selected form enhances yield, solubility, stability and chemical purity.
Bring your candidate to clinic faster with pre-formulation screening support
Our experienced material scientists support early pre-formulation screening to identify the most suitable form of your drug substance – with the right physicochemical properties to progress into preclinical and early clinical development. Our integrated approach streamlines decision-making, supports better candidate selection, and lays the foundation for a successful drug product.
Our end-to-end drug substance development capabilities bring together process research, analytical science, solid-state expertise and GMP manufacture – all from our state-of-the-art facility in Alnwick, UK. Working in close collaboration, we deliver tailored solutions for even the most complex development programs – from route selection and process optimisation to CPP definition, DoE, and impurity control.
With integrated solid-form screening and selection, we ensure the most suitable form is identified ahead of manufacture, supporting faster, smoother progression to IND/IMPD and beyond.
